Patient dies in MacroGenics' cancer study, FDA puts trial on hold
患者在MacroGenics的癌症研究中死亡，FDA叫停试验

The FDA has placed a partial clinical hold on MacroGenics’ Phase 2 study in gynecologic cancers after one patient died and three others experienced life-threatening side effects, the company disclosed Tuesday.
MacroGenics周二披露称，由于一名患者死亡、另有三名患者出现危及生命的不良反应，FDA已对该公司在妇科癌症领域的二期研究实施部分临床搁置。